Header Logo

Connection

Srinivas Vourganti to Humans

Back to Details
This is a "connection" page, showing publications Srinivas Vourganti has written about Humans.
Srinivas Vourganti
Connection Strength
0.647
Humans
  1. Metastasis-directed treatment in kidney cancer. Curr Opin Urol. 2023 09 01; 33(5):375-382.
    View in: PubMed
    Score: 0.049
  2. Pro: Magnetic Resonance Imaging Targeting Leads to Overtreatment of Prostate Cancer. J Urol. 2022 08; 208(2):246-247.
    View in: PubMed
    Score: 0.045
  3. Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis. BJU Int. 2022 07; 130(1):54-61.
    View in: PubMed
    Score: 0.044
  4. Assessing the diagnostic performance of systematic freehand PrecisionPoint transperineal prostate biopsy: Comparison of observed outcomes to PBCG nomogram predictions. Urol Oncol. 2022 01; 40(1):4.e9-4.e17.
    View in: PubMed
    Score: 0.043
  5. Spatial Tracking of Targeted Prostate Biopsy Locations: Moving Towards Effective Focal Partial Prostate Gland Ablation with Improved Treatment Planning. Curr Urol Rep. 2017 Oct 18; 18(12):93.
    View in: PubMed
    Score: 0.033
  6. Optimizing waiting duration for renal transplants in the setting of renal malignancy: is 2?years too long to wait? Nephrol Dial Transplant. 2017 Oct 01; 32(10):1767-1773.
    View in: PubMed
    Score: 0.033
  7. MR/US Fusion Technology: What Makes It Tick? Curr Urol Rep. 2017 Mar; 18(3):20.
    View in: PubMed
    Score: 0.031
  8. Implications of High Rates of Metastatic Prostate Cancer in BRCA2 Mutation Carriers. Prostate. 2016 09; 76(13):1135-45.
    View in: PubMed
    Score: 0.030
  9. Multiparametric magnetic resonance imaging and ultrasound fusion biopsy detect prostate cancer in patients with prior negative transrectal ultrasound biopsies. J Urol. 2012 Dec; 188(6):2152-2157.
    View in: PubMed
    Score: 0.023
  10. Surgical management of large renal tumors. Expert Rev Anticancer Ther. 2011 Dec; 11(12):1889-900.
    View in: PubMed
    Score: 0.022
  11. Ultrasonographic evaluation of renal infections. Radiol Clin North Am. 2006 Nov; 44(6):763-75.
    View in: PubMed
    Score: 0.015
  12. Single Port Robotic Pyeloplasty: early single-center experience. Int Braz J Urol. 2023 Nov-Dec; 49(6):757-762.
    View in: PubMed
    Score: 0.012
  13. Single-Port Robot-Assisted Radical Prostatectomy: Where Do We Stand? Curr Oncol. 2023 04 20; 30(4):4301-4310.
    View in: PubMed
    Score: 0.012
  14. Enzalutamide Monotherapy vs Active Surveillance in Patients With Low-risk or Intermediate-risk Localized Prostate Cancer: The ENACT Randomized Clinical Trial. JAMA Oncol. 2022 08 01; 8(8):1128-1136.
    View in: PubMed
    Score: 0.011
  15. Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions. Cancer. 2022 09 15; 128(18):3287-3296.
    View in: PubMed
    Score: 0.011
  16. Re: Oral Relugolix for Androgen-deprivation Therapy in Advanced Prostate Cancer. Eur Urol. 2021 09; 80(3):386.
    View in: PubMed
    Score: 0.011
  17. Moving away from systematic biopsies: image-guided prostate biopsy (in-bore biopsy, cognitive fusion biopsy, MRUS fusion biopsy) -literature review. World J Urol. 2021 Mar; 39(3):677-686.
    View in: PubMed
    Score: 0.010
  18. Urology Residents' Experience With Simulation: Initial Evaluation of MRI/US Fusion Biopsy Workshop. Urology. 2019 Dec; 134:51-55.
    View in: PubMed
    Score: 0.009
  19. Fusion prostate biopsy outperforms 12-core systematic prostate biopsy in patients with prior negative systematic biopsy: A multi-institutional analysis. Urol Oncol. 2018 Jul; 36(7):341.e1-341.e7.
    View in: PubMed
    Score: 0.009
  20. Epidermal Growth Factor Receptor (EGFR)-targeted Photoimmunotherapy (PIT) for the Treatment of EGFR-expressing Bladder Cancer. Mol Cancer Ther. 2017 10; 16(10):2201-2214.
    View in: PubMed
    Score: 0.008
  21. End-stage renal disease secondary to renal malignancy: Epidemiologic trends and survival outcomes. Urol Oncol. 2017 08; 35(8):529.e1-529.e7.
    View in: PubMed
    Score: 0.008
  22. The metastatic potential of renal tumors: Influence of histologic subtypes on definition of small renal masses, risk stratification, and future active surveillance protocols. Urol Oncol. 2017 04; 35(4):153.e15-153.e20.
    View in: PubMed
    Score: 0.008
  23. Re: Csaba Berczi, Ben Thomas, Zsolt Bacso, Tibor Flasko. Bilateral renal cancers: oncological and functional outcomes. Int Urol Nephrol 2016 (Epub ahead of print). Int Urol Nephrol. 2017 Feb; 49(2):267-268.
    View in: PubMed
    Score: 0.008
  24. Lack of Impact of Robotic Assisted Laparoscopic Radical Prostatectomy on Intraoperative Levels of Prostate Cancer Circulating Tumor Cells. J Urol. 2016 Apr; 195(4 Pt 1):1136-42.
    View in: PubMed
    Score: 0.007
  25. Chromophobe Renal Cell Carcinoma is the Most Common Nonclear Renal Cell Carcinoma in Young Women: Results from the SEER Database. J Urol. 2016 Apr; 195(4 Pt 1):847-51.
    View in: PubMed
    Score: 0.007
  26. Association of urinary bladder paragangliomas with germline mutations in the SDHB and VHL genes. Urol Oncol. 2015 Apr; 33(4):167.e13-20.
    View in: PubMed
    Score: 0.007
  27. Diagnostic value of biparametric magnetic resonance imaging (MRI) as an adjunct to prostate-specific antigen (PSA)-based detection of prostate cancer in men without prior biopsies. BJU Int. 2015 Mar; 115(3):381-8.
    View in: PubMed
    Score: 0.007
  28. Natural history of small index lesions suspicious for prostate cancer on multiparametric MRI: recommendations for interval imaging follow-up. Diagn Interv Radiol. 2014 Jul-Aug; 20(4):293-8.
    View in: PubMed
    Score: 0.007
  29. Imaging and pathology findings after an initial negative MRI-US fusion-guided and 12-core extended sextant prostate biopsy session. Diagn Interv Radiol. 2014 May-Jun; 20(3):234-8.
    View in: PubMed
    Score: 0.006
  30. Defining early-onset kidney cancer: implications for germline and somatic mutation testing and clinical management. J Clin Oncol. 2014 Feb 10; 32(5):431-7.
    View in: PubMed
    Score: 0.006
  31. MRI characterization of the dynamic effects of 5a-reductase inhibitors on prostate zonal volumes. Can J Urol. 2013 Dec; 20(6):7002-7.
    View in: PubMed
    Score: 0.006
  32. Adverse health outcomes associated with surgical management of the small renal mass. J Urol. 2014 Feb; 191(2):301-8.
    View in: PubMed
    Score: 0.006
  33. Accuracy of multiparametric magnetic resonance imaging in confirming eligibility for active surveillance for men with prostate cancer. Cancer. 2013 Sep 15; 119(18):3359-66.
    View in: PubMed
    Score: 0.006
  34. Can magnetic resonance-ultrasound fusion biopsy improve cancer detection in enlarged prostates? J Urol. 2013 Dec; 190(6):2020-2025.
    View in: PubMed
    Score: 0.006
  35. Magnetic resonance imaging/ultrasound-fusion biopsy significantly upgrades prostate cancer versus systematic 12-core transrectal ultrasound biopsy. Eur Urol. 2013 Nov; 64(5):713-719.
    View in: PubMed
    Score: 0.006
  36. Utility of multiparametric magnetic resonance imaging suspicion levels for detecting prostate cancer. J Urol. 2013 Nov; 190(5):1721-1727.
    View in: PubMed
    Score: 0.006
  37. Overall survival advantage with partial nephrectomy: a bias of observational data? Cancer. 2013 Aug 15; 119(16):2981-9.
    View in: PubMed
    Score: 0.006
  38. Estrogen receptor-? expression and pharmacological targeting in bladder cancer. Oncol Rep. 2013 Jul; 30(1):131-8.
    View in: PubMed
    Score: 0.006
  39. Pathologic validation of renal cell carcinoma histology in the Surveillance, Epidemiology, and End Results program. Urol Oncol. 2014 Jan; 32(1):23.e9-13.
    View in: PubMed
    Score: 0.006
  40. Low suspicion lesions on multiparametric magnetic resonance imaging predict for the absence of high-risk prostate cancer. BJU Int. 2012 Dec; 110(11 Pt B):E783-8.
    View in: PubMed
    Score: 0.006
  41. Outcomes of patients with surgically treated bilateral renal masses and a minimum of 10 years of followup. J Urol. 2012 Dec; 188(6):2084-8.
    View in: PubMed
    Score: 0.006
  42. Age-related changes in prostate zonal volumes as measured by high-resolution magnetic resonance imaging (MRI): a cross-sectional study in over 500 patients. BJU Int. 2012 Dec; 110(11):1642-7.
    View in: PubMed
    Score: 0.006
  43. Image guidance in the focal treatment of prostate cancer. Curr Opin Urol. 2012 Jul; 22(4):328-35.
    View in: PubMed
    Score: 0.006
  44. Impact of pathological tumour characteristics in patients with sarcomatoid renal cell carcinoma. BJU Int. 2012 Jun; 109(11):1600-6.
    View in: PubMed
    Score: 0.005
  45. Prostate-specific antigen/solvent interaction analysis: a preliminary evaluation of a new assay concept for detecting prostate cancer using urinary samples. Urology. 2011 Sep; 78(3):601-5.
    View in: PubMed
    Score: 0.005
  46. Threonine 22 phosphorylation attenuates Hsp90 interaction with cochaperones and affects its chaperone activity. Mol Cell. 2011 Mar 18; 41(6):672-81.
    View in: PubMed
    Score: 0.005
  47. Laparoendoscopic single-site nephrectomy: initial clinical experience in children. J Endourol. 2010 Dec; 24(12):1957-61.
    View in: PubMed
    Score: 0.005
  48. A Pfannenstiel single-site nephrectomy and nephroureterectomy: a practical application of laparoendoscopic single-site surgery. Urology. 2009 Sep; 74(3):482-5.
    View in: PubMed
    Score: 0.005
  49. Selective efficacy of depsipeptide in a xenograft model of Epstein-Barr virus-positive lymphoproliferative disorder. J Natl Cancer Inst. 2004 Oct 06; 96(19):1447-57.
    View in: PubMed
    Score: 0.003
  50. Experimental treatment of Epstein-Barr virus-associated primary central nervous system lymphoma. Cancer Res. 2003 Mar 01; 63(5):965-71.
    View in: PubMed
    Score: 0.003
  51. Successful treatment of posttransplantation lymphoproliferative disorder (PTLD) following renal allografting is associated with sustained CD8(+) T-cell restoration. Blood. 2002 Oct 01; 100(7):2341-8.
    View in: PubMed
    Score: 0.003
  52. GM-CSF and IL-2 induce specific cellular immunity and provide protection against Epstein-Barr virus lymphoproliferative disorder. J Clin Invest. 2001 Sep; 108(6):887-94.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.